Jade Biosciences, Inc., (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, has announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately US$45 million to the company, before offering expenses.
Latham & Watkins LLP is advising Jade Biosciences in the private placement financing with a corporate team led by San Diego partners Cheston Larson and Matt Bush, and counsel Anthony Gostanian, with assistance from Katie Raya.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
